Revised forecast
Fiscal year ending June 2026 · Full yearPrevious forecast published Earnings forecast: 14 August 2025; dividend forecast: 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the fourth quarter, transactions with pharmaceutical manufacturers in China continued to show signs of recovery, while transactions with major customers, mainly in Europe, remained stable and the company continued to secure solid profits. Following a review of recent earnings trends, foreign exchange trends and other factors, the outlook is now expected to exceed the previous forecast.
| Item | Details |
|---|---|
| Net Sales | ¥17,669 million → ¥18,180 million（+2.9%） |
| Operating profit | ¥1,224 million → ¥1,354 million（+10.6%） |
| Ordinary income | ¥1,186 million → ¥1,482 million（+24.9%） |
| Profit attributable to owners of the parent | ¥825 million → ¥1,032 million（+25.1%） |
| Net income per share | 272.3 yen and sen → 345.5 yen and sen |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | Earnings forecast: 14 August 2025; dividend forecast: 15 May 2026 |
| Previous-period results | Net sales: ¥18,785 million; operating profit: ¥1,318 million; ordinary profit: ¥1,158 million; net income attributable to owners of the parent: ¥736 million; net income per share: ¥240.15. Dividends paid were ¥38.00 per share for the year-end dividend and ¥76.00 per share for the full year. |
| Reason for the revision | In the fourth quarter, transactions with pharmaceutical manufacturers in China continued to show signs of recovery, while transactions with major customers, mainly in Europe, remained stable and the company continued to secure solid profits. Following a review of recent earnings trends, foreign exchange trends and other factors, the outlook is now expected to exceed the previous forecast. |
| Dividend forecast revision | The year-end dividend forecast has been revised from ¥61.00 to ¥63.00 per share, and the annual dividend forecast from ¥102.00 to ¥104.00 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fourth quarter, transactions with pharmaceutical manufacturers in China continued to show signs of recovery, while transactions with major customers, mainly in Europe, remained stable and secured profits. Following a further review of recent earnings trends, foreign exchange trends and other factors, the outlook is now expected to exceed the previous forecast.